Physician

Andrew Aaron Muskovitz, M.D.

According to 2025 Medicare claims, Andrew Muskovitz, M.D. (NPI: 1558544510) practices hematology/oncology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Macomb, MI. This provider's primary affiliated billing organization is MICHIGAN HEALTHCARE PROFESSIONALS PC (NPI: 1295023547; TIN: 451674932) and primary practice location at 48314-9998. Muskovitz is affiliated with the Honest ACO of Michigan LLC (ACO ID: D0236), participating under the REACH model.

Muskovitz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 840 traditional Medicare patients, billed 149,489 HCPCS/CPT codes, and received $2,087,194 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,845 prescription claims across 324 beneficiaries totaling $6,221,082 in drug costs, led by Revlimid (Lenalidomide). DME data shows 28 claims. Open Payments data shows 5 records totaling $104. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $186,369 to $2,087,194. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $844,887 to $6,221,082. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,074 to $617.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	454	6,465	$186,369
2016	589	62,473	$887,049
2017	666	134,954	$1,976,167
2018	709	159,866	$2,606,673
2019	832	126,337	$2,028,926
2020	844	135,936	$2,152,818
2021	911	168,199	$2,286,970
2022	915	183,816	$2,546,244
2023	878	181,606	$2,572,216
2024	840	149,489	$2,087,194

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	176	834	$844,887
2016	177	837	$1,032,787
2017	259	1,459	$1,375,248
2018	287	1,999	$3,205,984
2019	337	2,503	$3,306,882
2020	325	2,458	$4,271,536
2021	293	1,760	$2,776,295
2022	301	1,650	$2,831,426
2023	314	1,578	$3,509,244
2024	324	1,845	$6,221,082

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$188
2016	N/R	62	$31,325
2017	N/R	38	$8,336
2018	N/R	N/R	N/R
2019	N/R	17	$320
2020	N/R	59	$3,590
2021	N/R	81	$5,194
2022	N/R	N/R	N/R
2023	N/R	98	$20,841
2024	N/R	28	$477

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	100	287	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	243	455	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	232	315	$65
36415	Insertion of needle into vein for collection of blood sample	398	733	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	318	631	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	39	1,092	$805,065
Pomalyst	Pomalidomide	38	1,064	$734,329
Lenalidomide	Lenalidomide	40	1,120	$642,357
Cabometyx	Cabozantinib S-Malate	21	630	$399,172
Xtandi	Enzalutamide	28	840	$336,746

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$289
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$104	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Aaron Muskovitz, M.D.?

Tedicare shows public-source Medicare data for Andrew Aaron Muskovitz, M.D. (NPI 1558544510), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Aaron Muskovitz, M.D. have ACO affiliation data?

Andrew Aaron Muskovitz, M.D. is shown with ACO affiliation data for Honest ACO of Michigan LLC (REACH, ACO ID D0236).

What billing organization is linked to Andrew Aaron Muskovitz, M.D.?

Andrew Aaron Muskovitz, M.D. is linked to MICHIGAN HEALTHCARE PROFESSIONALS PC (billing NPI 1295023547) in the available physician profile data.

Does Andrew Aaron Muskovitz, M.D. have Open Payments data?

Andrew Aaron Muskovitz, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.